ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1082

The Journey of a Patient with Psoriatic Arthritis: The Path from Diagnosis to Treatment

Feyza Nur Azman1, Kadir Tanin2, Efe Sacin2, Enes Azman1, Melike Rizaoglu1, Ceren Uc1, Beste Acar1 and Serdal Ugurlu3, 1Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, 3Istanbul University-Cerrahpasa, Istanbul, Turkey

Meeting: ACR Convergence 2024

Keywords: Health Care, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal disease associated with psoriasis. This study was conducted to investigate the diagnostic journey to PsA, exploring the duration from symptom onset to diagnosis.

Methods: All reachable PsA patients registered in our clinic (between 2000 and 2024) were included and enrolled in the study survey.

Results: A total of 204 patients, with a mean age of 48.2 ± 12.2 years (range 20-77), were included in the study. The group consisted of 80 males and 124 females. Before receiving their PsA diagnosis, patients initially sought help from dermatology (34.1%), internal medicine (28.8%), and orthopedics (19.0%) (Table 1). Only 11.5% of patients directly visited a rheumatology department. Among patients who did not initially seek help from rheumatology, 37.7% were later referred to a rheumatology department at a training and research hospital or a university hospital for further evaluation, where they received a diagnosis of PsA (Table 2).

61.4% of the patients who first applied to rheumatology started their treatment after the workups and got their follow-up appointment. 26.5% of patients were applied to more than three specialists until their final diagnosis. 49.7% of them got their diagnosis at a university hospital. From their symptom onset to receiving a diagnosis, 33% of the patients spent around 1-5 years in total (Table 3). 44.6% of the patients continued their follow-up with the doctor who initially diagnosed them.

After the patients were diagnosed, 19.9% of them began their treatment right away. Among the tests conducted for the diagnosis, biopsy, and blood tests took the longest to complete for 50.8% of the patients. Specifically, 7.6% of the patients who underwent biopsy and blood tests reported that the process took about 2 months.

The latest treatment data shows that 59.9% of the patients had to switch to another medication. Patients typically had to wait about 3 months between appointments with the rheumatologist. Only 41.2% of the patients were able to secure their next appointment at the time of their current appointment.

In terms of their work life, 30.4% of the individuals reported that their disease did not affect their work. The biggest concern for 59.6% of the patients was the potential of their condition worsening and impacting their lives. Additionally, 17% of the patients were hesitant to disclose their diagnosis to friends and family. The most common issue affecting their social life was psoriasis, reported by 19.7% of the patients.

38.4% of the participants expressed confidence in future improvement in their condition, 30.8% were not optimistic, and 30.8% were uncertain.

Conclusion: These findings emphasize the need for standardized protocols, more awareness of the disease among patients, and a systematic pathway to prevent diagnosis delay and improve patient care in initial consultations for PsA. Significant frequent changes in healthcare providers post-diagnosis were highlighted, indicating the need for improvement.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: F. Azman: None; K. Tanin: None; E. Sacin: None; E. Azman: None; M. Rizaoglu: None; C. Uc: None; B. Acar: None; S. Ugurlu: None.

To cite this abstract in AMA style:

Azman F, Tanin K, Sacin E, Azman E, Rizaoglu M, Uc C, Acar B, Ugurlu S. The Journey of a Patient with Psoriatic Arthritis: The Path from Diagnosis to Treatment [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-journey-of-a-patient-with-psoriatic-arthritis-the-path-from-diagnosis-to-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-journey-of-a-patient-with-psoriatic-arthritis-the-path-from-diagnosis-to-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology